European Hematology Association: Treating Sickle Cell Disease and Beta-Thalassemia with CRISPR/Cas9 Gene Editing – PR Newswire (press release)
|
European Hematology Association: Treating Sickle Cell Disease and Beta-Thalassemia with CRISPR/Cas9 Gene Editing
PR Newswire (press release) Our approach is to use our CRISPR/Cas9 gene editing tool to re-create the small changes to the DNA that cause “Hereditary Persistence of Fetal Hemoglobin” and lead to expression of the protective fetal hemoglobin to reduce symptoms in patients with … |
|
European Hematology Association: Treating Sickle Cell Disease and Beta-Thalassemia with CRISPR/Cas9 Gene Editing
PR Newswire (press release) Our approach is to use our CRISPR/Cas9 gene editing tool to re-create the small changes to the DNA that cause “Hereditary Persistence of Fetal Hemoglobin” and lead to expression of the protective fetal hemoglobin to reduce symptoms in patients with … |
Q13 FOX |
Power of immunotherapy saves local man’s life
Q13 FOX SEATTLE — Far away from the buzz of city noise, along the open road in Fall City, a cyclist finds solace. “I think about what it feels like — the wind in my face, the sound. I feel how lucky I am to have gotten to this place.” It’s here, peppered … |
|
No space for data? Store it in DNA
The Straits Times The event was co-organised by the NUS’ Synthetic Biology for Clinical and Technological Innovation (SynCTI), the BioBricks Foundation and SynBioBeta, an international community of entrepreneurs, investors, policymakers and enthusiasts devoted to the … |